NetScientific PLC Vortex Announces First Commercial VTX-1 Sale (7197V)
07 Novembro 2017 - 5:00AM
UK Regulatory
TIDMNSCI
RNS Number : 7197V
NetScientific PLC
07 November 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences Announces First Commercial Sale of the VTX-1
Liquid Biopsy System
London, UK - 7 November 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, notes that its portfolio company, Vortex
BioSciences, today announced its first direct commercial sale of
its VTX-1 Liquid Biopsy System, a fully automated benchtop system
for collecting intact Circulating Tumour Cells (CTCs).
Vortex's VTX-1 Liquid Biopsy System automates the capture and
collection of viable CTCs directly from whole blood for analysis.
Circulating tumour cells, which are shed into the circulation,
offer researchers new insights into patients' cancer biology. Using
proprietary microfluidics technology, the Vortex VTX-1 traps
unlabeled CTCs in microscale vortices from whole blood, allowing
researchers to perform processes such as whole genome amplification
(WGA) and targeted next-generation sequencing (NGS) to better
understand cancer progression and potentially develop new methods
of disease identification and monitoring.
Commenting on the news, Francois Martelet, Chairman of Vortex
BioSciences Inc. and CEO of NetScientific said: "We are delighted
to announce the first sale of Vortex's VTX-1, which represents an
important step in the Company's commercialisation journey. The
system combines industry-leading purity and high CTC capture rates
of between 65%-75%, which we believe can give researchers the
opportunity to open new windows into our understanding of cancer.
Vortex Biosciences is a core element of NetScientific's portfolio,
and we believe the performance of the VTX-1 system and its ease of
use, will ensure it emerges as a leader in the highly exciting and
rapidly developing CTC field."
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe
Limited (NOMAD and Broker) Tel: +44 (0) 20 7710 7600
Jonathan Senior / David
Arch / Ben Maddison
Vortex Biosciences Tel: +1 (0) 415 823 7649
Steve Crouse steve@vortexbiosciences.com
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Vortex Biosciences Announces First Commercial Sale of the VTX-1
Liquid Biopsy System
The VTX-1 Liquid Biopsy System's Innovative Approach Represents
the Next Step in CTC Isolation Systems
MENLO PARK, CA, November 07 - Vortex Biosciences, provider of
circulating tumor cell (CTC) capture systems, today announced the
first commercial sale of the VTX-1 Liquid Biopsy System, a fully
automated benchtop system for collecting intact CTCs. The VTX-1
utilizes proprietary microfluidics to automate the isolation of
CTCs directly from whole blood based on the larger size and
deformability of the cells.
Shed by tumors into the circulation, CTCs offer a window into
the cancer biology of a patient. Isolating and characterizing CTCs
gives researchers new insight and the potential to transform our
understanding of cancer, improving the way cancer is diagnosed and
treated. However, capturing CTCs out of blood to enable
characterization is not easy. CTCs are relatively scarce, with
concentrations as low as 1-10 CTCs/mL of whole blood, against a
background of millions of white blood cells and billions of red
blood cells.
Vortex's VTX-1 Liquid Biopsy System automates the capture and
collection of viable CTCs directly from whole blood for analysis.
Using proprietary microfluidics, the VTX-1 traps unlabeled CTCs in
microscale vortices while red and white blood cells flow past.
After selective trapping into the microfluidic chambers, CTCs are
then released and collected into a container for downstream
analysis.
"We are excited to achieve our first commercial sale of the
VTX-1 Liquid Biopsy System." commented Gene Walther, Chief
Executive Officer at Vortex Biosciences. "The reaction to the VTX-1
throughout the marketplace has been unbelievably positive,
confirming both the tremendous potential CTCs offer and the unique
value of the VTX-1."
The VTX-1's innovative approach towards capturing CTCs offers a
number of advantages over other commercial CTC isolation systems.
With an automated and simple workflow, capacity for unbiased CTC
capture, high CTC recovery, high CTC purity and ease of integration
with downstream assays, the VTX-1 represents the next step in CTC
isolation systems.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument received CE
Mark and FDA Class 1 registration in 2016 and in 2017 launched in
US and Europe. It works by harvesting intact circulating tumor
cells from whole blood samples for use in downstream research and
clinical applications such as patient stratification in clinical
trials, monitoring disease progression and drug treatment
effectiveness. With a mission to enable noninvasive diagnosis of
cancer and real-time monitoring throughout a patient's treatment,
Vortex is at the forefront of accelerating cancer research and
improving patient outcomes. Vortex is a core subsidiary of
NetScientific plc, a transatlantic healthcare technology group with
an investment strategy focused on sourcing, funding and
commercializing technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
# # #
This information is provided by RNS
The company news service from the London Stock Exchange
END
PFUUNURRBVAARUA
(END) Dow Jones Newswires
November 07, 2017 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024